Jubilant Therapeutics reports preclinical information of double LSD1 and HDAC6 at AACR 2020 Kumar Jeetendra | June 23, 2020 Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The preclinical …
Newfound substance compound demonstrates potential to become treatment for mind issues Kumar Jeetendra | July 13, 2020 Researchers at IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) discovered a novel compound compound, that has got the capacity to became a new medication for the treatment of heart symptoms of brain ailments such as Down syndrome and pneumonia. These results are available in preclinical models where the new chemical ameliorated difficulties in cognitive …
MD Anderson and Sanofi work together to quicken improvement of imaginative malignant growth treatments Kumar Jeetendra | July 15, 2020 At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer. “Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via …
Drug discovery pipeline to exploit transcription factors for cancer therapy Kumar Jeetendra | July 21, 2020 Cancer is a major cause of death and among the most complicated challenges to contemporary medication. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up firm QUANTRO Therapeutics tries to radically change the precision and range of cell-based drug screening. QUANTRO’s …
Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals Kumar Jeetendra | July 25, 2020 Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. MRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune …
Nitric oxide treatment can be essential in the battle against COVID-19 Kumar Jeetendra | July 27, 2020 Nitric oxide therapy could be critical in the world’s struggle against SARS-CoV-2, the coronavirus which causes COVID-19, according to a review by the George Washington University (GW). Nitric oxide is an antimicrobial and anti inflammatory molecule with key roles in pulmonary arterial role in the context of viral infections as well as other pulmonary diseases. …
Study: Anti-microRNA sedate essentially lessens miR-92a levels in human peripheral blood Kumar Jeetendra | August 12, 2020 A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels from the blood of healthy humans. “According to documented, promising therapeutic possible, locked nucleic acid (LNA)-based anti-miR-92a was further developed and tested in a first in human analysis,” said Stefanie Dimmeler, PhD, Goethe University, Frankfurt, Germany and coauthors. “MRG-110 caused de-repression of …
Scientists distinguish new method that causes leukemia Kumar Jeetendra | August 13, 2020 Every year, 1.1 million new cases of blood cancers are diagnosed globally. Currently, chemotherapy remains the most common and efficient plan of treatment. On the other hand, the development of aggressive types of leukemia in adults stimulates a need for early detection and new therapeutic approaches to achieve better clinical outcomes. In a novel step …
CARE consortium dispatches to quicken drug discovery and improvement for COVID-19 Kumar Jeetendra | August 19, 2020 Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland, …
CRISPR-based framework smothers qualities identified with AAV antibody production Kumar Jeetendra | September 9, 2020 Gene therapy generally is based on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In the event of CRISPR-based gene therapies, molecular scissors can then snip out a faulty gene, add in a missing arrangement or enact a temporary change in its expression, but the body’s immune response to AAV can …
New AGA report subtleties adequacy and wellbeing of fecal microbiota transplantation Kumar Jeetendra | October 4, 2020 Now, the American Gastroenterological Association (AGA) released the first results in the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real world study about the effectiveness and safety of FMT. Published in Gastroenterology, the registry reported that FMT resulted in a treatment of Clostridioides difficile (C. difficile) infection in 90% of individuals across …
Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer Kumar Jeetendra | October 28, 2020 In this new role, Stewart will work as part of the Executive staff to drive Adaptate’s Business and Corporate Development activities. Stewart Kay, CBO, Adaptate Biotherapeutics Adaptate is developing a range of therapeutic antibodies that recognize drug targets and have the potential to modulate the activity of gamma delta T cells. Gamma delta T cells …
